Novan (NOVNW) Other Current Receivables : $0.00 Mil (As of Mar. 2023)

View and export this data going back to 2018. Start your Free Trial

What is Novan Other Current Receivables?

Novan's Other Current Receivables for the quarter that ended in Mar. 2023 was $0.00 Mil.

Novan Other Current Receivables Historical Data

The historical data trend for Novan's Other Current Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Novan Other Current Receivables Chart

Novan Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Other Current Receivables

Get a 7-Day Free Trial

Novan Quarterly Data
	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23
Other Current Receivables	Get a 7-Day Free Trial															-	-	-	-	-

Novan Other Current Receivables Calculation

GuruFocus uses a standardized financial statement format for all companies. GuruFocus lists Accounts Receivable, Notes Receivable , Loans Receivable and Other Current Receivables under the "Total Receivables" section.

Novan Other Current Receivables Related Terms

Thank you for viewing the detailed overview of Novan's Other Current Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Novan Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Novan Inc (OTCPK:NOVNW) » Definitions » Other Current Receivables

Comparable Companies

Traded in Other Exchanges

N/A

Address

P.O. Box 64, Pittsboro, NC, USA, 27312

Website

https://www.novan.com

NVN Liquidation Inc Formerly Novan Inc is a dermatology company focused on developing and commercializing therapeutic products for skin diseases. It is developing SB206 as a topical prescription gel for the treatment of viral skin infections. The company's product portfolio includes; Wynzora Cream for the treatment of plaque psoriasis, Rhofade cream for the treatment of persistent facial erythema, Minolira tablets to treat inflammatory lesions of non-nodular moderate to severe acne vulgaris in patients, Cloderm cream for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses, Sitavig tablets for the treatment of recurrent herpes labialis in immunocompetent adults, and Nuvail nail solution for managing signs and symptoms of nail dystrophy.